EN DE

Clicks Group (CLCGY) Fair Value & Analysis

Healthcare · US · Market cap $3.3B

CG Clicks Group logo Clicks Group CLCGY · US
Price$26.81
Fair Value$34.63
Upside+29.2%
Quality74/100
Watch Clicks Group for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 6.7% net margin
Low debt · generates free cash flow
3.70% dividend yield
Ranks above peers (11/11)
Moderate moat 63/100
Evidence: High Range $25.97 – $43.29 Share as image

Fair value as of: Jul 15, 2026

From 26 valuation models · updated 26 days ago

Fair value updated Jul 15, 2026, revised from $34.29 to $34.63 (+1.0%) since Jun 24, 2026. Share price −3.7% over the past month.

A solid business, screening 29% undervalued on our models.

What matters now

  • The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict.
  • Our model range runs from $25.97 (bear) to $43.29 (bull), base $34.63. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 74/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$44.57 $22.01 Fair Value $34.63 Sep 2020 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range $22.01 – $44.57 · fair‑value band $25.97 – $43.29 · the $26.81 price screens below the $34.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Clicks Group (CLCGY) currently trades at $26.81, while our model-based Fair Value estimate is $34.63, implying the stock looks roughly 29.2% undervalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Clicks Group generated revenue of $49.5B at a net margin of 6.7%. Revenue grew 7.4% year over year. It earns a return on equity of 53.3%. Net debt stands at $3.5B. Fundamentals as of Jul 15, 2026

Our scenario range runs from $25.97 (bear case) to $43.29 (bull case); at $26.81, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 29%, CLCGY screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF $435.70 $682.14 $1,059 80
Residual Income $173.27 $225.93 $1,601 76
Rev-Margin DCF $393.34 $628.08 $914.66 74
All 26 models by family
DCF Models
FCF DCF $434.71 $694.07 $1,100 38
Owner Earnings $422.96 $674.82 $1,069 31
5Y Revenue Exit $393.34 $630.04 $939.69 39
5Y EBITDA Exit $483.44 $806.76 $1,197 41
5Y P/E Exit $419.64 $681.63 $967.20 38
10Y Revenue Exit $393.30 $614.77 $929.45 36
10Y EBITDA Exit $461.49 $737.86 $1,130 37
10Y P/E Exit $420.96 $650.70 $950.90 35
Earnings-Based
Graham-Dodd $183.52 $706.70 $957.85 54
Lynch FV $172.67 $246.68 $320.68 50
PEG = 1.0 $172.67 $246.68 $320.68 46
EPV $291.69 $333.37 $369.32 59
Dividend Discount
Gordon GGM $139.99 $278.94 $422.39 70
DDM Multi-Stage $139.99 $241.07 $294.44 61
Multiples
P/E Multiple $425.07 $566.77 $708.46 63
P/S Multiple $344.11 $458.81 $573.51 58
P/B Multiple $241.17 $321.57 $401.96 55
EV/EBIT $525.21 $691.03 $856.84 53
EV/EBITDA $561.18 $738.99 $916.80 54
EV/Revenue $382.80 $534.96 $687.12 43
Asset-Based
NCAV (Graham) $29.23 $39.17 $58.47 50
Growth DCF
Growth DCF $435.70 $682.14 $1,059 80
Rev-Margin DCF $393.34 $628.08 $914.66 74
Economic Profit
Residual Income $173.27 $225.93 $1,601 76
ROIC Compounder $302.54 $358.61 $415.76 72
Growth Earnings
Growth-Adj P/E $312.03 $445.76 $579.48 68

Widest divergence: DCF Models ($674.82) versus Asset-Based ($39.17). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) $49.5B
Revenue growth (YoY) +7.4%
Net margin 6.7%
Return on equity 53.3%
Free cash flow $4.2B FY2025
P/E ratio 16.1
More key figures
Operating margin 9.1%
EPS (TTM) $1.75
Dividend yield 3.7%
EPS growth (YoY) +8.3%
Net debt $3.5B FY2025

Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 74/100

Of which business quality 73 · Market factors (momentum, volatility) 29

Profitability 83
Margins and returns on capital today
Quality Growth 58
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 76
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 86
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Clicks Group Limited, together with its subsidiaries, operates as a health, wellness, and beauty retailer in South Africa and internationally. The company operates through two segments, Retail and Distribution.

Full company description

Clicks Group Limited, together with its subsidiaries, operates as a health, wellness, and beauty retailer in South Africa and internationally. The company operates through two segments, Retail and Distribution. It provides retail, including Clicks, a specialist health, beauty and homeware retailer; Sorbet, a franchise of hair and beauty salons; 180 Degrees Marketing, a software development company; and The Body shop, which specializes in naturally inspired luxury toiletries, cosmetics, gifting and grooming, with stores. The company also offers various ranges of mother-and-baby products, including baby hardware, accessories, health, food, diaper and wipes, and baby toiletries under the Clicks Baby brand; and diabetic clinic, travel clinic, and wound management practice under the M-KEM brand. In addition, the company is involved in the wholesale and supply of pharmaceutical products to retail pharmacies, private hospitals, dispensing doctors, and retail health stores under the UPD brand. The company was formerly known as New Clicks Holdings Limited and changed its name to Clicks Group Limited in June 2009. Clicks Group Limited was founded in 1968 and is headquartered in Cape Town, South Africa.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Clicks Group reported revenue of $50.0B in FY2025 versus $37.3B in FY2021, a compound +7.6%/yr. Reported net income was $3.2B in FY2025, compounding +14.5%/yr from FY2021.

Growth Quality 81/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$50.0B
Latest YoY
+10.1%
Avg. growth/yr (3Y)
+8.1%
Avg. growth/yr (5Y)
+7.8%
Avg. growth/yr (23Y)
+10.1%
Revenue +7.6%/yr
FY21 $37.3B
FY22 $39.6B
FY23 $41.6B
FY24 $45.4B
FY25 $50.0B
Net income +14.5%/yr
FY21 $1.8B
FY22 $2.6B
FY23 $2.5B
FY24 $2.8B
FY25 $3.2B

Watch CLCGY: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Clicks Group Fair Value". https://www.fairvalue-calculator.com/stock/CLCGY

Peer Group

Pharmaceutical Retailers · 61 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 74 · Top 25%
Fair Value upside +29% · Top 25%
Return on equity (TTM) 53% · Top 25%
Return on assets 14% · Top 25%
Net margin (TTM) 7% · Top 25%
Operating margin (TTM) 9% · Top 25%
Revenue growth 7% · Above median
Dividend yield (TTM) 3.7% · Above median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 16.1× · Cheaper than median
P/FCF 0.8× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 72 · sector 21
FUTURE 37 · sector 19
PAST 100 · sector 19
HEALTH 100 · sector 97
DIVIDEND 74 · sector 66

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$39.20 HK$33.28 -15%
Raia Drogasil S.A RADL3 R$18.20 R$15.58 -14%
Yifeng Pharmacy Chain Co 603939 ¥20.24 ¥29.07 +44%
DaShenLin Pharmaceutical Group 603233 ¥17.81 ¥23.86 +34%
Corporativo Fragua, S.A. FRAGUAB 463.00 MXN 821.18 MXN +77%
LBX Pharmacy Chain Joint Stock Company 603883 ¥11.51 ¥10.57 -8%
MedPlus Health Services Limited MEDPLUS ₹690.20 ₹379.25 -45%
Yixintang Pharmaceutical Group 002727 ¥11.46 ¥9.45 -18%
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.40 ¥10.05 -30%
Apotea AB APOTEA kr 74.75 kr 43.95 -41%

Compare Clicks Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Clicks Group (CLCGY) overvalued or undervalued?
As of Jul 15, 2026, our model estimates a fair value of $34.63 versus a price of $26.81, about +29% (undervalued).
What is the fair value of CLCGY?
Our model-based fair value for Clicks Group is $34.63 (as of Jul 15, 2026), built from audited fundamentals. The current price is $26.81.
What is the quality score of CLCGY?
Clicks Group has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Clicks Group (CLCGY)?
Clicks Group reported trailing-twelve-month revenue of about $49.5B (latest available figure, as of Jul 15, 2026).
What is the net profit margin of CLCGY?
The net profit margin of Clicks Group is about 6.7%, meaning it keeps roughly 6.7% of revenue as net income. Based on the latest reported figures.
Does Clicks Group pay a dividend?
Clicks Group currently shows a dividend yield of about 3.70% relative to its recent price (as of Jul 15, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Clicks Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.